Serum insulin-like growth factor 1 (IGF-1) measured at baseline is not a useful predictor of growth hormone deficiency (GHD) in adults who have experienced traumatic brain injuries, according to a recent study.
Neuroendocrine disorders such as adult growth hormone deficiency (AGHD) are becoming increasingly recognized after a traumatic brain injury (TBI), but diagnostic tools like the insulin tolerance test (ITT) and glucagon stimulation test (GST) may not always be feasible for growth hormone stimulation testing (GHST).
“Our findings add to a growing body of literature documenting pituitary dysfunction secondary to sport-related concussion,” stated author Kirstie Lithgow, BSc, MD, and her colleagues in their study. “This can present with isolated or multiple pituitary hormone deficits, with GHD being the most common isolated deficit.”
Adults with GHD are defined as individuals with either a congenital growth hormone deficiency transitioning to adulthood or developing the condition spontaneously or through trauma. In addition to idiopathic and congenital causes, adult growth hormone deficiency AGHD can be caused by factors such as radiation, pituitary surgery, autoimmune disease, inflammation, and pituitary tumors.
The warning signs of AGHD are diverse, spanning both physical and psychological symptoms, and can include:
- Weight gain
- Problems sleeping
- Fatigue and lack of energy
- Muscle fatigue
- Decreased sexual desire
- Depression, nervousness, and anxiety
- Feelings of hopelessness